Stockscreener 앱 받기
53.51
1.29%
-0.70
Crispr Therapeutics Ag 주식(CRSP)의 최신 뉴스
Meme Stocks: Will CRISPR Therapeutics AG benefit from geopolitical trendsJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
Price Action: Is CRISPR Therapeutics AG showing insider buyingJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Nwam LLC Purchases 83,454 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG (CRSP) Gets a Buy from Bank of America Securities - The Globe and Mail
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Aug Summary: Can CRISPR Therapeutics AG maintain its current growth rateEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
A Look At CRISPR Therapeutics (CRSP) Valuation As 2026 Gene Editing Milestones Come Into Focus - Sahm
Is CRISPR Therapeutics (CRSP) Using J.P. Morgan Spotlight to Recast Its Gene-Editing Leadership Story? - Sahm
CRISPR Therapeutics: Patience And Opportunity Through Volatility (NASDAQ:CRSP) - Seeking Alpha
Sumitomo Mitsui Trust Group Inc. Sells 251,163 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - sharewise.com
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and NeoGenomics (NEO) - The Globe and Mail
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know - MSN
What's Driving the Market Sentiment Around CRISPR Therapeutics AG? - Benzinga
CRSP: Casgevy and next-gen gene editing platforms drive growth, with 2026 set as a pivotal year - TradingView — Track All Markets
2 Biotech Stocks That Could Soar This Year - Finviz
CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True? - Finviz
CRSP: Regulatory Submissions for CASGEVY Expected by Mid-2026 - GuruFocus
CRSP Outlines Strategic Goals and Milestones for 2026 - GuruFocus
CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies - TipRanks
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones - The Manila Times
CRISPR Therapeutics Highlights Program Advancements - TradingView — Track All Markets
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next - TechStock²
CRISPR Therapeutics Reports Q3 2025 Financial Results - MSN
Avoiding Lag: Real-Time Signals in (CRSP) Movement - Stock Traders Daily
Is CRISPR Therapeutics (CRSP) Attractive After Recent Gene Editing Progress And Mixed Returns? - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - sharewise.com
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next - TechStock²
Revenue Check: How CRISPR Therapeutics AG stock valuations compare to rivalsStop Loss & Detailed Earnings Play Strategies - moha.gov.vn
Quarterly Risk: Is CRISPR Therapeutics AG stock a contrarian buyJuly 2025 Setups & Community Verified Watchlist Alerts - ulpravda.ru
Can CRISPR Therapeutics AG stock beat market expectations this quarterTreasury Yields & Real-Time Market Sentiment Reports - ulpravda.ru
Why global investors buy CRISPR Therapeutics AG (1CG) stock2025 Technical Patterns & Real-Time Market Sentiment Reports - ulpravda.ru
CRISPR Therapeutics AG CFO Sells Shares Under Trading Plan - TradingView — Track All Markets
Institutional Investors Are CRISPR Therapeutics AG's (NASDAQ:CRSP) Biggest Bettors and Were Rewarded After Last Week's US$529m Market Cap Gain - 富途牛牛
Is CRISPR Therapeutics AG stock positioned for long term growthVolatility Index Analysis & Free Discover Dynamic Stocks - ulpravda.ru
Aug Outlook: Why CRISPR Therapeutics AG (1CG) stock could be next leaderQuarterly Trade Report & Capital Efficient Trading Techniques - moha.gov.vn
Is CRISPR Therapeutics (CRSP) Attractively Priced After Recent Gene Editing Progress? - simplywall.st
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why - sharewise.com
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 8.7%Still a Buy? - MarketBeat
Chardan maintains a buy recommendation on CRISPR Therapeutics AG (CRSP) - MSN
Why CRISPR Therapeutics (CRSP) Soared on Friday? - MSN
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Assessing CRISPR Therapeutics (CRSP) Valuation As Investor Interest Returns - simplywall.st
Assessing CRISPR Therapeutics' (CRSP) Valuation After Recent Share Price Volatility - Yahoo Finance
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
Crispr Therapeutics: Prospects For 2026Why I Believe Casgevy Is Key (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics AG Stock Analysis and ForecastInsider Trading Compliance & Unlock Free Weekly Portfolio Checkups - earlytimes.in
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next - TechStock²
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? - The Globe and Mail
4.73%
0.92%
자본화:
|
볼륨(24시간):